Segall Bryant & Hamill, LLC Fate Therapeutics Inc Transaction History

Segall Bryant & Hamill, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $1.62 Million - $3.91 Million	164,235 New	164,235 $1.66 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $3.22 Million - $5.52 Million	153,051 New	153,051 $3.43 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $791,441 - $1.89 Million	44,513 Added 42.19%	150,013 $3.72 Million
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $7,298 - $14,828	246 Added 0.23%	105,500 $4.09 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $236,808 - $318,483	4,950 Added 4.93%	105,254 $6.16 Million
Q3 2021 Nov 03, 2021	BUY	$59.27 - $95.73 $2.26 Million - $3.65 Million	38,091 Added 61.23%	100,304 $5.95 Million
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $223,606 - $307,629	3,325 Added 5.65%	62,213 $5.4 Million
Q1 2021 May 13, 2021	SELL	$72.16 - $117.4 $804,656 - $1.31 Million	-11,151 Reduced 15.92%	58,888 $4.86 Million
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $49,478 - $131,134	-1,299 Reduced 1.82%	70,039 $6.37 Million
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $1.57 Million - $2.1 Million	51,741 Added 264.03%	71,338 $2.85 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $396,055 - $690,402	19,597 New	19,597 $672,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.